DUBLIN, December 10, 2014 /PRNewswire/ --
Dublin - Research and Markets(http://www.researchandmarkets.com/research/hzc93s/dendritic_cell) has announced the addition of the"Dendritic Cell and CAR-T Therapies, 2014 - 2024"report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeutics including cell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).
DCT makes use of autologous or allogenic Antigen Presenting Cells (APCs) to stimulate the immune system to recognise and act against the tumors. In April 2010, the FDA approval of Sipuleucel-T (PROVENGE, manufactured by Dendreon Corporation), a dendritic cell vaccine, gave a push to the concept of DCT. However, the vaccine hasn't been able to meet the high expectations. Despite this, the overall DCT outlook is promising; late stage development vaccines such as AGS-003, DCVax-L, DCVAC/PCa and Eltrapuldencel-T are likely to carry forward the baton.
With the similar aim to stimulate the body's immune system, CAR-T uses the patient's autologous effector T-cells, modifying it with a synthetic receptor enabling it to increase the tumor specific immune response. This therapy is expected to first enter market with the launch of CTL019 by Novartis in the next few years. In recent trials, CTL019 has shown complete remission in children with advanced cases of treatment-resistant ALL. Apart from Novartis, some other big pharmaceutical companies including Pfizer have entered the space. Juno Therapeutics, Takara Bio and Kite Pharma are other active players.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Cancer Therapeutics and Immuno-Oncology
4. Current Market Landscape
5. Dendritic Cell Therapy: Key Molecules and Future Outlook
6. Chimeric Antigen Receptor-T Cell Therapy
7. Company Profiles
8. Interview Transcripts
9. Conclusion
10. Appendix 1: Tabulated Data
11. Appendix 2: List of Companies and Organisations
Companies Mentioned:
- Activartis Biotech
- Argos Therapeutics
- Artecel
- Asterias Biotherapeutics
- BMS
- Bayer Healthcare
- Bellicum Pharmaceuticals
- Cabaret Biotech Limited
- California Stem Cell, Inc.
- Cancer Research Technology
- Cancer Research UK
- Celdara Medical
- Celgene Corporation
- Cellectis
- Cellular Biomedicine Group
- Centre Memorial SloanKettering Cancer
- Ciba-Geigy
- City of Hope Medical Center
- Cognate
- DCPrime
- DanDrit Biotech
- Delta-Vir Immunotherapeutics
- Dendreon
- Duke University
- Fraunhofer Institute
- Fred Hutchinson Cancer Research Center
- Fujifilm Diosynth Biotechnologies
- Genentech
- Genetix Pharmaceuticals
- German Research Foundation
- Geron
- GlaxoSmithKline
- Green Cross Corporation
- Horizon Technology Finance
- Immunicum
- ImmunoCellular Therapeutics
- JW CreaGene
- Jichi Medical University Hospital
- Johnson and Johnson
- Juno Therapeutics
- Kings College
- Kiromic
- Kitasato Institute
- Kite Pharma
- Masonic Cancer Center
- MediGene
- Medical School of Charles
- Medinet
- Memorial Sloan Kettering Cancer Centre
- Merck
- National Cancer Institute
- NeoStem
- Northwest Biotherapeutics
- Novartis
- Onyx Pharmaceuticals
- OriBase Pharma
- Orpechem Peptide Chemicals
- Oxford BioMedica
- PPF Group
- Paul Ehrlich Institute
- Pfizer
- PharmaCell
- Pharmstandard International
- Prima BioMed
- Progenitor Cell Therapy LLC
- Regen BioPharma
- Roche
- Rockefeller University
- SOTIO
- Sandoz
- Seattle Children's Hospital
- Signifix
- TILT Biotherapeutics
- Takara Bio
- Technological Developments
- Tella
- Trianta Immunotherapies
- University of Antwerp
- University of Gent
- University of Pennsylvania
- University of Wisconsin
- VU University Medical Center
- Vlaams Instituutvoor Biotechnologie
- bluebird bio
For more information visithttp://www.researchandmarkets.com/research/hzc93s/dendritic_cell
Media Contact:Laura Wood, +353-1-481-1716, press@researchandmarkets.net
